Haoxi Health Technology Ltd (HAO) Stock Analysis
Verdict: AVOID
Collapsing revenue and razor-thin margins make this micro-cap a high-risk vehicle prone to volatility decay and fundamental decay.
Investment score: 18/100
Analysis as of
Is Haoxi Health Technology Ltd stock worth reviewing? AI model thesis
Avoid. The company shows declining revenue, structural margin weakness, and extreme price instability.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 12/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Haoxi Health Technology Ltd opportunities and risks
What speaks for HAO
- Cash Position Ratio
What speaks against HAO
- Margin Compression to Zero
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HAO | n/a | 0.0x | 3.1x | 4.8% | -6.5% | -241.7% |
| ABLV | n/a | 0.2x | 51.1x | 11.8% | 1.6% | 2.3% |
| WIMI | 0.1x | 0.6x | n/a | 26.0% | 71.1% | 43.4% |
| Peer median | n/a | 0.4x | 25.0x | 18.9% | 36.3% | 22.9% |
Frequently asked questions about Haoxi Health Technology Ltd (HAO)
Is HAO stock a good investment?
The cached TradeMates AI model rates Haoxi Health Technology Ltd as AVOID with an investment score of 18/100. Avoid. The company shows declining revenue, structural margin weakness, and extreme price instability. This is algorithmic model output, not personal investment advice.
Is HAO stock a buy?
The TradeMates model verdict for HAO is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.